SEC Company Response from BioNexus Gene Lab (BGLC) — Apr 2, 2019
BioNexus Gene Lab Corp
Date: April 2, 2019 · CIK: 0001737523 · Accession: 0001551163-19-000065
AI Filing Summary & Sentiment
File numbers found in text: 333-229399
Letter
Via EDGAR SECURITIES AND EXCHANGE COMMISSION Securities and Exchange Commission Division of Corporate Finance Washington DC 20549 Re: BioNexus Gene Lab Corporation File No. 333-229399
Dear Mr. Regan:
BioNexus Gene Lab Corporation hereby requests, pursuant to Rule 461 under the Securities Act of 1933, as amended, that the above-referenced registration statement be accelerated to 4:00 PM, Eastern Time, on Friday, April 3, 2019, or as soon thereafter as practicable.
The Company hereby acknowledges that:
°
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
°
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
°
the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions concerning this matter, please contact Daniel H. Luciano, Esq., counsel for the Company.
Sincerely,
BioNexus Gene Lab Corporation
Show Raw Text
CORRESP 1 filename1.htm Converted by EDGARwiz BIONEXUS GENE LAB CORP. Level 8, Tower 8, Avenue 5, The Horizon Bangar South No. 8 Jalan Kerinchi 59200 Kuala Lumpur Malaysia April 2, 2016 Via EDGAR SECURITIES AND EXCHANGE COMMISSION Securities and Exchange Commission Attn: Mr. Ruairi Regan Division of Corporate Finance Washington DC 20549 Re: BioNexus Gene Lab Corporation File No. 333-229399 Dear Mr. Regan: BioNexus Gene Lab Corporation hereby requests, pursuant to Rule 461 under the Securities Act of 1933, as amended, that the above-referenced registration statement be accelerated to 4:00 PM, Eastern Time, on Friday, April 3, 2019, or as soon thereafter as practicable. The Company hereby acknowledges that: ° should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; ° the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and ° the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. If you have any questions concerning this matter, please contact Daniel H. Luciano, Esq., counsel for the Company. Sincerely, BioNexus Gene Lab Corporation /s/ Chi Yuen Leong Chi Yuen Leong President